Oryn Therapeutics Advances Next Phase of Orynotide™ Platform with Expanded Leadership and Board
Oryn announced a series of strategic developments advancing its next-generation Orynotide™ platform — appointing Guy Rosenthal, Ph.D., as president and CEO and Paul Carrington, Ph.D., as SVP of discovery & early development, strengthening its board with Paul Sekhri (executive chairman) and Nina Kjellson (director), and entering a Catalyze agreement with Lilly ExploR&D.
Read Full Release →